Assessing cost-effectiveness of hepatitis C testing pathways in Georgia using the Hep C Testing Calculator

Sci Rep. 2021 Nov 1;11(1):21382. doi: 10.1038/s41598-021-00362-y.

Abstract

The cost of testing can be a substantial contributor to hepatitis C virus (HCV) elimination program costs in many low- and middle-income countries such as Georgia, resulting in the need for innovative and cost-effective strategies for testing. Our objective was to investigate the most cost-effective testing pathways for scaling-up HCV testing in Georgia. We developed a Markov-based model with a lifetime horizon that simulates the natural history of HCV, and the cost of detection and treatment of HCV. We then created an interactive online tool that uses results from the Markov-based model to evaluate the cost-effectiveness of different HCV testing pathways. We compared the current standard-of-care (SoC) testing pathway and four innovative testing pathways for Georgia. The SoC testing was cost-saving compared to no testing, but all four new HCV testing pathways further increased QALYs and decreased costs. The pathway with the highest patient follow-up, due to on-site testing, resulted in the highest discounted QALYs (123 QALY more than the SoC) and lowest costs ($127,052 less than the SoC) per 10,000 persons screened. The current testing algorithm in Georgia can be replaced with a new pathway that is more effective while being cost-saving.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use
  • Cost-Benefit Analysis
  • Female
  • Georgia (Republic) / epidemiology
  • Hepacivirus / isolation & purification
  • Hepatitis C / diagnosis*
  • Hepatitis C / drug therapy
  • Hepatitis C / economics
  • Hepatitis C / epidemiology
  • Humans
  • Male
  • Markov Chains
  • Mass Screening / economics
  • Microbiological Techniques / economics
  • Quality-Adjusted Life Years

Substances

  • Antiviral Agents